Lexaria Bioscience Corp. entered into contracts with a contract research organization to conduct its 2026 Animal Study #2 (GLP‑1‑A26‑2), testing the compatibility of two next‑generation glucagon‑like peptide‑1 drugs—amycretin, owned by Novo Nordisk, and retatrutide, owned by Eli Lilly—with the company’s DehydraTECH delivery platform.
The study design has been finalized, formulation manufacturing is underway, and dosing is expected to begin within 30 days. Eighteen distinct study arms will evaluate pharmacokinetics and tolerability, with the goal of demonstrating that DehydraTECH can reduce gastrointestinal side effects while maintaining efficacy for these high‑profile drugs.
Lexaria’s DehydraTECH platform is engineered to improve oral drug delivery and tolerability, positioning the company to capture a share of the projected $122 billion GLP‑1 market. By testing amycretin and retatrutide, Lexaria aims to generate new intellectual‑property claims that could support future licensing agreements and broaden its commercial footprint.
The company’s focus on DehydraTECH is supported by a growing patent portfolio and an improved cash position. In the fiscal year ending August 31 2025, Lexaria reported a net loss of $11.9 million, and in the third quarter of fiscal 2025 the loss was $3.8 million. CEO Richard Christopher noted that next‑generation GLP‑1 drugs are under development and that Lexaria intends to establish DehydraTECH’s benefits in these drugs that have not yet reached the marketplace.
The new animal study strengthens Lexaria’s pre‑clinical portfolio, enhances its competitive positioning in the GLP‑1 space, and lays the groundwork for potential future revenue streams through licensing and intellectual‑property monetization.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.